These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 27112193)

  • 1. Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use.
    Smith MA; Gertig D; Hall M; Simms K; Lew JB; Malloy M; Saville M; Canfell K
    BMC Health Serv Res; 2016 Apr; 16():147. PubMed ID: 27112193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combined impact of implementing HPV immunisation and primary HPV screening in New Zealand: Transitional and long-term benefits, costs and resource utilisation implications.
    Hall MT; Smith MA; Lew JB; O'Hallahan J; Fentiman G; Neal H; Sage M; Canfell K
    Gynecol Oncol; 2019 Mar; 152(3):472-479. PubMed ID: 30876491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program.
    Lew JB; Simms KT; Smith MA; Hall M; Kang YJ; Xu XM; Caruana M; Velentzis LS; Bessell T; Saville M; Hammond I; Canfell K
    Lancet Public Health; 2017 Feb; 2(2):e96-e107. PubMed ID: 29253402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Routine cervical screening by primary HPV testing: early findings in the renewed National Cervical Screening Program.
    Machalek DA; Roberts JM; Garland SM; Thurloe J; Richards A; Chambers I; Sivertsen T; Farnsworth A
    Med J Aust; 2019 Aug; 211(3):113-119. PubMed ID: 31168828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Projected Impact of HPV and LBC Primary Testing on Rates of Referral for Colposcopy in a Canadian Cervical Cancer Screening Program.
    Coldman AJ; Phillips N; van Niekerk D; Smith L; Krajden M; Cook D; Quinlan DJ; Ehlen T; Miller D; Stuart GC; Peacock S; Martin RE; Franco EL; Ogilvie G
    J Obstet Gynaecol Can; 2015 May; 37(5):412-420. PubMed ID: 26168101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country.
    Velentzis LS; Caruana M; Simms KT; Lew JB; Shi JF; Saville M; Smith MA; Lord SJ; Tan J; Bateson D; Quinn M; Canfell K
    Int J Cancer; 2017 Dec; 141(12):2410-2422. PubMed ID: 28801947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017-2035: Example from Australia.
    Hall MT; Simms KT; Lew JB; Smith MA; Saville M; Canfell K
    PLoS One; 2018; 13(2):e0185332. PubMed ID: 29444073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer.
    Ogilvie GS; Krajden M; van Niekerk D; Smith LW; Cook D; Ceballos K; Lee M; Gentile L; Gondara L; Elwood-Martin R; Peacock S; Stuart G; Franco EL; Coldman AJ
    Int J Cancer; 2017 Jan; 140(2):440-448. PubMed ID: 27685757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cervical cancer prevention in Australia: Planning for the future.
    Saville AM
    Cancer Cytopathol; 2016 Apr; 124(4):235-40. PubMed ID: 26619381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introducing human papillomavirus (HPV) primary testing in the age of HPV vaccination: projected impact on colposcopy services in Wales.
    Pesola F; Rebolj M; Leeson S; Dunk L; Pickford L; Gjini A; Sasieni P
    BJOG; 2021 Jun; 128(7):1226-1235. PubMed ID: 33247993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic accuracy of high-risk HPV DNA genotyping for primary cervical cancer screening and triage of HPV-positive women, compared to cytology: preliminary results of the PIPAVIR study.
    Chatzistamatiou K; Moysiadis T; Angelis E; Kaufmann A; Skenderi A; Jansen-Duerr P; Lekka I; Kilintzis V; Angelidou S; Katsiki E; Hagemann I; Tsertanidou A; Koch I; Boecher O; Soutschek E; Maglaveras N; Agorastos T
    Arch Gynecol Obstet; 2017 May; 295(5):1247-1257. PubMed ID: 28337594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achieving cervical cancer elimination: The simulated impacts of HPV vaccination and transitioning from liquid-based cytology to HPV-based screening test.
    Balqis-Ali NZ; Anis-Syakira J; Fun WH; Mohd Said Z; Abdul Samad S; Zainal Abidin N; Zulkepli J; Ahmad N; Mohd Abas MN; Yong CM; Yusof SN; Daud NA; Sararaks S
    PLoS One; 2024; 19(7):e0307880. PubMed ID: 39052665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
    Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
    Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of replacing cytology with human papillomavirus testing for cervical cancer screening on the prevalence of
    Hui BB; Reulein CP; Guy RJ; Donovan B; Hocking JS; Law MG; Regan DG
    Sex Transm Infect; 2018 May; 94(3):216-221. PubMed ID: 29326178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HPV testing and vaccination in Europe.
    Leeson SC; Alibegashvili T; Arbyn M; Bergeron C; Carriero C; Mergui JL; Nieminen P; Prendiville W; Redman CW; Rieck GC; Quaas J; Petry KU
    J Low Genit Tract Dis; 2014 Jan; 18(1):61-9. PubMed ID: 23774078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expenditure and resource utilisation for cervical screening in Australia.
    Lew JB; Howard K; Gertig D; Smith M; Clements M; Nickson C; Shi JF; Dyer S; Lord S; Creighton P; Kang YJ; Tan J; Canfell K
    BMC Health Serv Res; 2012 Dec; 12():446. PubMed ID: 23216968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of primary human papillomavirus triage approaches among vaccinated women in Norway: A model-based analysis.
    Portnoy A; Pedersen K; Sy S; Tropé A; Engesaeter B; Kim JJ; Burger EA
    Int J Cancer; 2024 Mar; 154(6):1073-1081. PubMed ID: 38088449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis.
    Simms KT; Laprise JF; Smith MA; Lew JB; Caruana M; Brisson M; Canfell K
    Lancet Public Health; 2016 Dec; 1(2):e66-e75. PubMed ID: 29253419
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.